Cancer survival among children and adolescents at a state referral hospital in southeastern Brazil

Sobrevida do câncer em crianças e adolescentes em hospital de referência estadual na região sudeste do Brasil

Abstract
Objectives: to analyze the patient characteristics and evaluate overall survival, survival according to demographic variables, the most common tumor groups and subgroups, the stages of disease, and risk factors after at least 5 years among children and adolescents with cancer who were admitted to a state referral hospital between 2000 and 2005.

Methods: the Kaplan-Meier method was employed to estimate survival. The survival curves were compared using the log-rank test. The Cox regression model was used to estimate the effect of independent variables.

Results: a total of 571 new cases were registered. The most frequent cancer groups were leukemia (34%), lymphoma (18%), and central nervous system (CNS) tumors (15%). The overall survival rate was 59%. The risk factors associated with lower survival were an age of more than 4 years or less than 1 year, the presence of CNS tumors, and non-localized disease.

Conclusion: although this was not a population-based study, it provides important epidemiological information about a state where population data on childhood and adolescent cancer are scarce and where hospital-based data do not exist. The survival rate found here should serve as a framework for future improvements, helping to guide policymakers focused on pediatric oncology in the state.

Key words Cancer, Children, Adolescents, Survival analysis

Resumo
Objetivos: analisar as características dos pacientes, avaliar sobrevida global e sobrevida de acordo com variáveis demográficas, grupos e subgrupos dos tumores mais comuns, extensão da doença e fatores de risco após pelo menos cinco anos em crianças e adolescentes com câncer, admitidos em hospital de referência estadual entre 2000 e 2005.

Métodos: método de Kaplan-Meier foi utilizado para estimar função de sobrevida. Curvas de sobrevida foram comparadas utilizando teste de log-rank. Modelo de Regressão de Cox foi utilizado para estimar o efeito das variáveis independentes.

Resultados: um total de 571 novos casos foi analisado. Os grupos mais frequentes foram leucemias (34%), linfomas (18%) e tumores do sistema nervoso central (SNC) (15%). Taxa de sobrevida global foi 59%. Fatores de risco associados à menor sobrevida: idade superior a quatro anos ou menor de um ano, presença de tumores do SNC e doença não localizada.

Conclusões: embora não seja um estudo populacional, este trabalho fornece importantes informações epidemiológicas de um estado onde estudos de base populacional do câncer na infância e adolescência são escassos e hospitalares não existem. A taxa de sobrevida encontrada deve servir como um marco para melhorias futuras ajudando os formuladores de políticas com foco na área de oncologia pediátrica no Estado.

Palavras-chave Câncer, Criança, Adolescente, Análise de sobrevida
Introduction

In Brazil, it is estimated that nearly 3% of all new cases of cancer occur in individuals who are less than 19 years old. The proportion of childhood cancers is related to the population structure. Low-income countries have younger median ages and higher proportions of children in their populations than do high-income countries. In Africa as a whole, 4.8% of cancers occur in children younger than 15 years, compared with only 0.4% in Europe. Overall, an estimated 11,530 cases among Brazilians under 19 years old were reported in 2012, which corresponds to a median incidence of 160 per million (154.3 per million children). Approximately 230 of these cases are expected to occur in the State of Espírito Santo (ES) in southeastern Brazil.

Advances in childhood (ages 0-14 years) and adolescent (ages 15-19 years) cancer treatment and in diagnostic techniques have resulted in an increase in survival in developed countries over the last four decades. The five-year survival has increased from less than 30% in the 1960s to approximately 80% in the 2000s for all childhood cancers and occasionally surpasses 90% in certain subgroups.

Multiple interrelated factors are responsible for the outlook for childhood cancer. Factors inherent to the disease itself affect survival rates (e.g., the type of tumor and its location). However, improvements in the survival of children and adolescents with cancer have been observed over the past few decades, including the integration of high-quality referral centers, clinical research, and education, and an approach to primary care emphasizing the early detection and improvement of pediatric cancer units by well-trained healthcare professionals. Indeed, the strong link between the quality of care and research activities depends on the alignment of systematic investment and national healthcare priorities to support the improvement of care for children with cancer.

In 2011, cancer was the second leading cause of death (7.9% of the total) in Brazil for people aged between 1 and 19 years, surpassed only by accidents.

The aim of the present study was to analyze the characteristics and overall survival after at least 5 years of children and adolescents aged under 19 years who were admitted to the Hospital Infantil Nossa Senhora da Glória (HINSG), the exclusive state referral center, for cancer treatment between 2000 and 2005. The study also aimed to analyze survival according to different demographic variables, groups of diseases, stages of disease, and the most common disease subgroups and risk factors.

Methods

A survival study was conducted using hospital-based, retrospective secondary data.

The HINSG is a general pediatric hospital located in Vitória, Espírito Santo, a state in southeastern Brazil, and it is the exclusive state referral center of the Sistema Único de Saúde - SUS (Unified Health System) for the treatment of cancer in individuals under 19 years of age. Every year, nearly 100 children and adolescents from all areas of ES and neighboring states are referred to this center for the treatment of various malignancies. Bone marrow transplants (BMTs) and local treatment for retinoblastoma (RB) are not provided in the state of ES through the SUS.

The study population consisted of children (aged 0-14 years) and adolescents (aged 15-18 years and 364 days) who were admitted to the HINSG between January 2000 and December 2005 as new cases of primary malignant neoplasms. Patients with a history of treatment with chemotherapy or radiotherapy and patients who had a second neoplasm or a benign neoplasm, except for neoplasms of the central nervous system (CNS), were excluded from this study.

Groups and subgroups were created in accordance with the third edition of the International Classification of Childhood Cancer, 3rd version (ICCC-3). Cases of nonmalignant tumors of the brain and CNS were thus included in the sample.

All of the neoplasms were confirmed cytomorphologically or histopathologically, except for certain CNS tumors for which a biopsy could not be performed because of technical and surgical limitations. In these cases, diagnoses were made using imaging studies.

The data were obtained from the information included in the medical records of the HINSG Oncology Unit. This study examined the number of cases by sex, age group, state of origin, most frequent groups and subgroups of disease, and the extent of disease. These variables were considered as predictors in the survival model, whose exposure variable was the survival time in months.

To generate a standardized staging system in order to be able to analyze the several types of tumors together, the following categories were established to indicate the extent of disease: local disease, stages I and II; regional disease, stage III; and metastatic disease, stage IV. This variable was not assessed in cases of leukemia or CNS tumors. The
following clinical staging systems, which have been adopted worldwide by collaborative groups focusing on childhood and adolescent cancer treatment, were adopted to control this variable: Ann Arbor staging for Hodgkin’s lymphoma (HL), Murphy staging for non-Hodgkin’s lymphoma (NHL), the National Wilms’ Tumor Study Group staging for nephroblastoma, Evans staging for neuroblastoma (NB), the tumor-node-metastasis (TNM) cancer staging system for bone tumors, and the TNM staging system for soft tissue tumors in cases of osteosarcoma (OTS) or rhabdomyosarcoma (RMS).

Special attention was paid to leukemia, lymphoma, and CNS tumors, which are the most frequent forms of cancer in these age groups.

The outcome variable was the time (in months) from the date of diagnosis until death from cancer (the event of interest). Other related events (discharge from the health service, abandonment of treatment, and loss to follow-up) were censored. The deadline to determine the patients’ outcomes was December 31st, 2010.

A follow-up analysis was conducted by examining the medical records for at least 60 months after a diagnostic conclusion. The Health Mortality Information System, made available by the State of Espírito Santo Department of Health, provided confirmation and the dates of deaths that did not occur in the HINSG.

A survival analysis was used to analyze the data. The Kaplan-Meier method was used to determine the overall survival time and the survival time according to the study variables. The survival curves were compared among the different categories using the log-rank method. A multivariate Cox proportional hazard model (hazard ratio, or HR) was used to verify the independent effects of the study variables that had a statistical significance of up to 10%. Tests were performed to verify the proportionality of the risks (Schoenfeld residuals, test of proportional hazard in the Cox model, and graphical tests) and to analyze the model residual (martingale residual graphics and deviance from the fitted model). The final significance level adopted in the model was 5%.

The statistical analysis of the data was performed using Statistical Package for the Social Sciences (SPSS) software (version 18.0) and the R language.

The present study was conducted in accordance with Resolution 196/96 of the National Health Council and was approved by the HINSG’s Human Research Ethics Committee (number 88/2010) on November 23rd, 2010.

Results

The sample population consisted of 571 patients with new cases of cancer who were admitted during the 6-year study period. Among the subjects, there was a survival rate of 59% after 5 years, and 247 patients died. The mean survival time was 82.7 (95% CI, 77.3-88.1) months (maximum observation time of 120 months), with a standard error of 2.7 months. Figure 1 shows the survival function calculated from the Kaplan-Meier curves for the outcome of death from cancer.

Figure 1
Survival curve using the Kaplan-Meier method for 571 children and adolescents under 19 years of age admitted to the HINSG with new cases of cancer. City of Vitória, ES, Brazil. 2000-2005.
Table 1 shows a description of the survival time according to the independent variables of interest. Figures 2A and 2B show the Kaplan-Meier curves that reflect the results in the table for the most frequent groups and the extent of the disease, respectively.

Table 1

<table>
<thead>
<tr>
<th>Clinical-epidemiological variables</th>
<th>N</th>
<th>%</th>
<th>Deaths</th>
<th>Mean</th>
<th>95% LL</th>
<th>95% UL</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>276</td>
<td>48.0</td>
<td>107</td>
<td>88.8</td>
<td>81.5</td>
<td>96.1</td>
<td>0.078</td>
</tr>
<tr>
<td>Male</td>
<td>295</td>
<td>52.0</td>
<td>140</td>
<td>75.6</td>
<td>68.7</td>
<td>82.5</td>
<td></td>
</tr>
<tr>
<td>Age group (in years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>41</td>
<td>7.0</td>
<td>18</td>
<td>79.5</td>
<td>60.9</td>
<td>98.1</td>
<td>0.011</td>
</tr>
<tr>
<td>1-5</td>
<td>191</td>
<td>34.0</td>
<td>68</td>
<td>87.5</td>
<td>79.3</td>
<td>95.7</td>
<td></td>
</tr>
<tr>
<td>5-10</td>
<td>151</td>
<td>26.0</td>
<td>61</td>
<td>87.9</td>
<td>78.2</td>
<td>97.7</td>
<td></td>
</tr>
<tr>
<td>10-15</td>
<td>137</td>
<td>24.0</td>
<td>74</td>
<td>63.2</td>
<td>54.2</td>
<td>72.1</td>
<td></td>
</tr>
<tr>
<td>15-19</td>
<td>51</td>
<td>9.0</td>
<td>26</td>
<td>68.0</td>
<td>52.2</td>
<td>83.9</td>
<td></td>
</tr>
<tr>
<td>Region of origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Espírito Santo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>72</td>
<td>13.0</td>
<td>35</td>
<td>69.3</td>
<td>56.9</td>
<td>81.6</td>
<td>0.605</td>
</tr>
<tr>
<td>Central</td>
<td>77</td>
<td>13.0</td>
<td>30</td>
<td>87.3</td>
<td>74.4</td>
<td>100.2</td>
<td></td>
</tr>
<tr>
<td>Metropolitan</td>
<td>296</td>
<td>52.0</td>
<td>130</td>
<td>82.3</td>
<td>75.1</td>
<td>89.5</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>63</td>
<td>11.0</td>
<td>29</td>
<td>73.3</td>
<td>59.0</td>
<td>87.7</td>
<td></td>
</tr>
<tr>
<td>Other States</td>
<td>63</td>
<td>11.0</td>
<td>23</td>
<td>81.9</td>
<td>68.8</td>
<td>95.0</td>
<td></td>
</tr>
<tr>
<td>Most common ICC-3 groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I Leukemia</td>
<td>194</td>
<td>34.0</td>
<td>87</td>
<td>76.7</td>
<td>68.7</td>
<td>84.7</td>
<td>0.001</td>
</tr>
<tr>
<td>II Lymphoma</td>
<td>101</td>
<td>18.0</td>
<td>23</td>
<td>96.2</td>
<td>86.9</td>
<td>105.5</td>
<td></td>
</tr>
<tr>
<td>III CNS tumors</td>
<td>84</td>
<td>15.0</td>
<td>45</td>
<td>62.2</td>
<td>49.7</td>
<td>74.8</td>
<td></td>
</tr>
<tr>
<td>IV-XII Other</td>
<td>192</td>
<td>33.0</td>
<td>92</td>
<td>77.4</td>
<td>68.1</td>
<td>86.8</td>
<td></td>
</tr>
<tr>
<td>I-XII Total</td>
<td>571</td>
<td>100.0</td>
<td>247</td>
<td>82.7</td>
<td>77.3</td>
<td>88.1</td>
<td></td>
</tr>
<tr>
<td>Most common ICC-3 subgroups (n=415)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I (a) Acute lymphocytic leukemia</td>
<td>141</td>
<td>*73.0</td>
<td>58</td>
<td>82.8</td>
<td>73.8</td>
<td>91.7</td>
<td>0.001</td>
</tr>
<tr>
<td>I (b) Acute myeloid leukemia</td>
<td>42</td>
<td>*22.0</td>
<td>24</td>
<td>57.2</td>
<td>38.9</td>
<td>75.4</td>
<td></td>
</tr>
<tr>
<td>II (a) Hodgkin’s lymphoma</td>
<td>31</td>
<td>*31.0</td>
<td>4</td>
<td>89.6</td>
<td>81.9</td>
<td>97.3</td>
<td></td>
</tr>
<tr>
<td>II (b) Non-Hodgkin’s and non-Burkitt’s lymphoma</td>
<td>23</td>
<td>*23.0</td>
<td>7</td>
<td>88.8</td>
<td>68.3</td>
<td>109.3</td>
<td></td>
</tr>
<tr>
<td>II (c) Burkitt’s lymphoma</td>
<td>30</td>
<td>*30.0</td>
<td>11</td>
<td>69.5</td>
<td>51.4</td>
<td>87.6</td>
<td></td>
</tr>
<tr>
<td>III (b) Astrocytoma</td>
<td>30</td>
<td>*36.0</td>
<td>13</td>
<td>75.4</td>
<td>55.0</td>
<td>95.7</td>
<td></td>
</tr>
<tr>
<td>IV (a) Neuroblastoma</td>
<td>26</td>
<td>*90.0</td>
<td>17</td>
<td>48.8</td>
<td>32.0</td>
<td>65.7</td>
<td></td>
</tr>
<tr>
<td>VI (a) Nephroblastoma</td>
<td>47</td>
<td>*87.0</td>
<td>8</td>
<td>114.2</td>
<td>102.2</td>
<td>126.2</td>
<td></td>
</tr>
<tr>
<td>VIII (a) Osteosarcoma</td>
<td>23</td>
<td>*70.0</td>
<td>10</td>
<td>73.4</td>
<td>54.7</td>
<td>92.1</td>
<td></td>
</tr>
<tr>
<td>IX (a) Rhabdomyosarcoma</td>
<td>22</td>
<td>*61.0</td>
<td>14</td>
<td>58.8</td>
<td>36.1</td>
<td>81.6</td>
<td></td>
</tr>
<tr>
<td>Extent of disease () (n=286)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local</td>
<td>105</td>
<td>37.0</td>
<td>22</td>
<td>111.2</td>
<td>100.9</td>
<td>121.6</td>
<td>0.001</td>
</tr>
<tr>
<td>Regional</td>
<td>98</td>
<td>34.0</td>
<td>37</td>
<td>84.0</td>
<td>72.4</td>
<td>95.5</td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>83</td>
<td>29.0</td>
<td>50</td>
<td>54.6</td>
<td>43.9</td>
<td>65.3</td>
<td></td>
</tr>
</tbody>
</table>

ICCC-3= International Classification of Childhood Cancer, 3rd version; * Proportion in relation to the reference group; † In total, 278 cases of leukemia and CNS tumors were excluded. No information was available for seven patients.
278 cases of leukemia and CNS tumors were excluded from the analysis of the extent of the disease. We analyzed the disease variables for 10 groups comprising a total of 286 cases. Data could not be obtained from the medical records for seven patients (2.4%). Advanced diseases (regional and metastatic) were the most common, representing 63% of cases. As this variable was correlated with the survival time, the Cox regression analysis was performed with an N of 286 patients.

The patients’ ages varied from 22 days to 18 years and 11 months. The majority of patients were in the 1- to 4-year age group (34%). Most subjects were male (52%), with a male-to-female ratio of 1.1/1.

508 patients (89%) lived in the state of ES, and an absolute majority lived in the metropolitan area of Vitória. The neighboring state of Bahia was home to 9% of the patients.

In the 12 groups, leukemia was the most frequent malignant neoplasm (34%), and acute lymphocytic leukemia was the most frequent subgroup (73%). The second most frequent group was lymphoma (18%), which was predominantly represented by HL and Burkitt’s lymphoma (BL). HL and BL accounted for 31% and 30% of the lymphoma subgroups, respectively. CNS tumors were the third most common neoplasm (15%), and astrocytoma (AST) was the most common subgroup (36%). Combined, these three groups comprised most of the cases (67%). The remaining 33% of the cases were tumors of the sympathetic nervous system (5%), Rb (<1%, two cases), renal tumors (9%), liver tumors (<1%), bone tumors (6%), soft tissue sarcomas (7%), germ cell tumors (3%), carcinomas (2%), and other unspecified malignant tumors (<1%, one case).

Table 1 shows the main functions of unadjusted survival for the study variables. The probability of overall survival for girls was higher than for boys, although this difference was not statistically significant (p=0.078). There were differences in the probability of survival according to age group (p=0.011) and the three most frequent groups of cancer (p=0.001) (Figure 2A). Comparison of the 10 most common subgroups revealed differences in terms of the probability of overall survival (p=0.001). Advanced disease was associated with a significant reduction in the probability of survival (Figure 2B). Figures 2A and 2B show excessive mortality after the 60-month survival period for CNS tumors and regional diseases.
There were no differences in survival associated with the patients’ region of origin.

The probability of survival was calculated for the 10 most frequent subgroups, totaling 415 cases (Table 2). Higher survival was found for individuals with HL (90.3%) and nephroblastoma (83%) at 60 months. In addition, all deaths from BL occurred within the first 12 months after the date of diagnosis. Patients with acute myeloid leukemia (AML) had one of the lowest mean survival rates, both at 3 (66.7%) and 60 (42.9%) months. As cases of NB and RMS advanced, the survival time steadily decreased. The lowest survival rates occurred at the end of the 5-year period.

After adjusting for variables in the model, the multivariate analysis showed that males had a 1.39 (1.07-1.81) times greater risk of death (Table 3). Similarly, infants (< 1 year old), older children (the 5- to 9- and 10- to 14-year age groups), and adolescents had 1.68, 1.37, 1.96, and 1.64 times greater risk of death, respectively, compared with the risk in the 1- to 4-year age group. Patients with leukemia or CNS tumors showed 6.75 and 9.11 times greater risk of death than patients with lymphoma. Regional and metastatic diseases were associated with a significantly higher risk of death. These patients had 2.64 and 4.47 times the risk associated with local diseases, respectively.

In the Cox analysis, we tested the assumptions of the proportional hazard model by graphing the Schoenfeld residuals. Using hypothesis testing, the violation of the assumption was observed for sex and the most frequent ICCC-3 groups, which after a new graphic analysis, did not present evidence of serious violation of the assumption of proportional risks for these variables. In the residual analysis, the martingale residuals suggested the presence of two atypical points (less than -2). However, when the deviance residuals, which are less asymmetric than the martingale residuals, were analyzed, the observed outliers were deemed to be acceptable. We conclude that there is evidence that the model adequately fits the data.

### Table 2

Probability of survival for the 10 most frequent subgroups of cancer in children and adolescents under 19 years of age admitted to the HINSG with new cases of cancer. Vitória, ES, Brazil, 2000-2005.

<table>
<thead>
<tr>
<th>Subgroup – ICCC-3</th>
<th>N</th>
<th>3 months</th>
<th>6 months</th>
<th>12 months</th>
<th>24 months</th>
<th>36 months</th>
<th>48 months</th>
<th>60 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (a) Acute lymphocytic leukemia</td>
<td>141</td>
<td>87.9</td>
<td>86.5</td>
<td>80.1</td>
<td>73.0</td>
<td>67.4</td>
<td>63.1</td>
<td>62.4</td>
</tr>
<tr>
<td>I (b) Acute myeloid leukemia</td>
<td>42</td>
<td>66.7</td>
<td>61.9</td>
<td>50.0</td>
<td>47.6</td>
<td>47.6</td>
<td>45.2</td>
<td>42.9</td>
</tr>
<tr>
<td>II (a) Hodgkin’s lymphoma</td>
<td>31</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>96.8</td>
<td>93.5</td>
<td>90.3</td>
<td>90.3</td>
</tr>
<tr>
<td>II (b) Non-Hodgkin’s and non-Burkitt’s lymphoma</td>
<td>23</td>
<td>100.0</td>
<td>95.7</td>
<td>87.0</td>
<td>73.9</td>
<td>73.9</td>
<td>69.6</td>
<td>69.6</td>
</tr>
<tr>
<td>III (c) Burkitt’s lymphoma</td>
<td>30</td>
<td>90.0</td>
<td>90.0</td>
<td>86.7</td>
<td>73.3</td>
<td>66.7</td>
<td>66.7</td>
<td>63.3</td>
</tr>
<tr>
<td>III (b) Astrocytoma</td>
<td>26</td>
<td>96.2</td>
<td>88.5</td>
<td>76.9</td>
<td>50.0</td>
<td>38.5</td>
<td>34.6</td>
<td>34.6</td>
</tr>
<tr>
<td>IV (a) Neuroblastoma</td>
<td>47</td>
<td>97.9</td>
<td>97.9</td>
<td>97.9</td>
<td>89.4</td>
<td>87.2</td>
<td>85.1</td>
<td>83.0</td>
</tr>
<tr>
<td>VI (a) Nephroblastoma</td>
<td>23</td>
<td>100.0</td>
<td>95.7</td>
<td>87.0</td>
<td>69.6</td>
<td>69.6</td>
<td>60.9</td>
<td>60.9</td>
</tr>
<tr>
<td>VIII (a) Osteosarcomas</td>
<td>22</td>
<td>95.5</td>
<td>86.4</td>
<td>72.7</td>
<td>54.5</td>
<td>54.5</td>
<td>45.5</td>
<td>40.9</td>
</tr>
<tr>
<td>IX (a) Rhabdomyosarcoma</td>
<td>415</td>
<td>89.1</td>
<td>85.3</td>
<td>78.3</td>
<td>68.3</td>
<td>64.3</td>
<td>60.1</td>
<td>59.0</td>
</tr>
</tbody>
</table>

ICCC-3= International Classification of Childhood Cancer, 3rd version.
Table 3
Hazard ratios associated with the study variables and a multivariate model of 571 new cases of cancer among children and adolescents under 19 years of age admitted to the HINSG. City of Vitória, ES, Brazil, 2000-2005.

<table>
<thead>
<tr>
<th>Clinical-epidemiological variables</th>
<th>N</th>
<th>Unadjusted hazard ratio</th>
<th>Cox adjusted hazard ratio (N=286)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>p-value estimate 95% LL 95% UL</td>
<td>p-value estimate 95% LL 95% UL</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>276</td>
<td>0.080 1</td>
<td>0.013 0.125 0.97 1.6</td>
</tr>
<tr>
<td>Male</td>
<td>295</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age group (in years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>41</td>
<td>0.014 1.34 0.79 2.25</td>
<td>0.003 1.68 0.99 2.87</td>
</tr>
<tr>
<td>1–5</td>
<td>191</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5–10</td>
<td>151</td>
<td>0.018 1.15 0.81 1.63</td>
<td>0.037 1.37 0.96 1.96</td>
</tr>
<tr>
<td>10–15</td>
<td>137</td>
<td>1.72 1.23 2.29</td>
<td>1.96 1.39 2.77</td>
</tr>
<tr>
<td>15–19</td>
<td>51</td>
<td>1.63 1.04 2.57</td>
<td>1.64 1.02 2.84</td>
</tr>
<tr>
<td><strong>Most frequent ICCC-3 groups</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td>101</td>
<td>0.001 1</td>
<td>0.001 1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>194</td>
<td>2.15 1.35 3.4</td>
<td>6.75 0.87 51.86</td>
</tr>
<tr>
<td>CNS tumors</td>
<td>84</td>
<td>3.03 1.83 5.01</td>
<td>9.11 1.18 70.55</td>
</tr>
<tr>
<td>Other</td>
<td>192</td>
<td>2.28 1.44 3.6</td>
<td>3.45 2.13 5.62</td>
</tr>
<tr>
<td><strong>Extent of disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local</td>
<td>105</td>
<td>0.001 1</td>
<td>0.001 1</td>
</tr>
<tr>
<td>Regional</td>
<td>98</td>
<td>2.10 1.24 3.56</td>
<td>2.64 1.55 4.51</td>
</tr>
<tr>
<td>Metastatic</td>
<td>83</td>
<td>4.01 2.42 6.65</td>
<td>4.47 2.68 7.46</td>
</tr>
</tbody>
</table>

ICCC-3: International Classification of Childhood Cancer, 3rd version; * In total, 278 cases of leukemia and CNS tumors were excluded. The extent of disease data for seven patients could not be obtained from the medical records.

Discussion

This is the first descriptive analysis of childhood and adolescent cancer in the state of ES, where data on childhood and adolescent cancer are limited to the information found in the population-based cancer registries (PBCRs) of the Metropolitan Area of Vitória (the capital and five neighboring cities) for the year 1997 alone.3,13,14

The proportional distribution of the three most common cancers found in the HINSG study according to the ICCC-3 is similar to that reported by 14 Brazilian PBCRs (Vitória was not included because the data covered less than 3 years), which have shown that the main groups of cancers are leukemia (18-41%), lymphoma (13-24%), and CNS tumors (7-17%).3

In other areas, leukemia has been reported to represent 25-35% of all cases. Leukemia was also the most common cancer (34%) in our study, occurring predominantly in acute forms. The second commonest childhood cancer in the HINSG series was lymphoma (18%), followed by CNS tumors (15%). The order of frequency of these first three groups differs from the observations of PBCRs in developed countries, where CNS tumors are more common than lymphomas. However, the order is compatible with results found in the medical literature for countries displaying the characteristics of developing countries, including Brazil.3,13,15-18

The order of frequency of subgroups in our series was similar to that found in other population studies. The percentage of the acute lymphoid leukemias (73%) in the present study is in accordance with the literature, in which this subgroup totaled 75-80% of all leukemias.15,17 Likewise, the astrocytoma subgroup (36%) predominated among the CNS tumors, showing a similar trend to that of other populations in all countries. This finding was also consistent with the results of a Brazilian study conducted at a single center, where astrocytomas represented 37% of CNS tumors in patients less than 21 years old.15,19

The possibility that the HL and BL subgroups are associated with Epstein-Barr virus (EBV) (an association observed in certain Brazilian regions20 and low-income countries where the endemic form predominates2,21) could explain the high proportions.
of cancers in these subgroups (31% and 30%, respectively) in the present study. There is a high prevalence of anti-EBV antibodies in the population of Vitória. This may explain the high proportion of lymphomas in our study, but it is also possible that CNS tumors were underdiagnosed, which would explain the lower number of cases compared with lymphoma. These observations need to be explored in further population-based registry studies.

According to data from a European PBCR, for all types of cancer, boys of any age have a higher risk of cancer than girls (overall sex ratio of 1.2:1). However, this ratio varies between different groups and subgroups of neoplasia. Between 1983 and 2005, the hospital-based cancer registry of the Instituto Nacional de Câncer observed that, of all cancer cases in children and adolescents, 54.5% were male, and 45.5% were female. Cancer in males was slightly more prevalent than in females, with a ratio of 1.1:1 in the HINSG study.

The pattern of diagnosis varies greatly between age groups, but on the whole, children at 1-4 years of age have the highest rates of diagnosis in most PBCRs. In the present study, the most common age range was 1-4 years old (34%). Therefore, the results obtained in this study concerning the sex ratio and the most prevalent age group are similar to those found in other populations.

The analysis of survival time enabled comparisons to be made between different categories of each study variable. The following were significant risk factors for lower survival rates in the HINSG sample: a higher age (compared with the 1- to 4-year age group), an age younger than 1 year, the presence of CNS tumors, and advanced-stage disease. There were no significant differences in survival rates for gender. In general, these results are comparable with those reported in a population-based setting.

The survival rates varied between different groups and subgroups. Of the 10 most frequent subgroups in this analysis, the highest 5-year survival rates were found for HL and nephroblastoma, whereas the worst outcomes were recorded for neuroblastoma, AML, and rhabdomyosarcoma. The low survival rate of patients with neuroblastoma or rhabdomyosarcoma in the HINSG sample can be partially attributed to the large number of patients with advanced stages of the disease. According to the literature, survival is inversely proportional to the advanced stage of disease, which underlines the benefits of early therapeutic intervention.

Overall, the 5-year survival rate for all cancers combined for children and adolescents diagnosed at the HINSG between 2000 and 2005 was 59%. The survival rates for childhood cancers vary substantially from country to country around the world. The 5-year survival rates reported by the EUROCare-4 study for all cancers combined were 81% in children and 87% in adolescents/young adults diagnosed with cancer between 1995 and 2002. In Shanghai, China, from 2002-2005, the rate was 55.7%. In sub-Saharan Africa, the overall 5-year survival varies from 5% in Côte d’Ivoire (before 2001) to 70% in South Africa.

It is important to note that 5-year survival is not equivalent to cure. In a large population-based study in Nordic European countries, the 5-year survivors who died during subsequent follow-up experienced recurrence or progression of the primary tumor or had a second malignancy. Some patients also died from causes unrelated to cancer and its treatment. The decline in the curves corresponding to survival rates beyond 5 years observed in the present study indicates a need for future follow-up studies focusing on the causes of death and the risk factors. These studies will allow therapies to address the causes of death. It would also be interesting to investigate the morbidity and the quality of life of the survivors.

The establishment of effective population-based childhood cancer registries is one of the key policies for improving the care of children with cancer around the world.

The analytical limitations of this study primarily concern the scarcity of PBCR data in the state of ES. It was thus difficult to make comparisons with other referral services in Brazil or with the population data for cancer in children and adolescents from the state of ES. For these reasons, it was not possible to correlate the cases admitted to the HINSG from the state of ES (508 cases in 6 years) with the incidence of cases in the state as a whole.

The present study cannot provide incidence rates for the populations from which all of the cases arose. Therefore, the data may not be representative of all cancer cases occurring in the area. However, the distribution of the cases among the disease groups and subgroups and the characteristics of the individuals (i.e., age and sex) in this analysis are similar to those found in PBCR studies. One reason for this result is that our hospital is the single public state treatment center for oncologic diseases, with the exception of Rb, among children and adolescents. This feature favors the convergence of a representative portion of the population. However, the interference of triage bias in the results cannot be excluded because other children and adolescents with better financial conditions or other characteristics are
treated by private practices in the city of Vitória or
go to another treatment center in another state. There
is a substantial need for future population-based
studies to establish the reliability of the relationship
between the groups and subgroups of neoplasms
among children and adolescents in the state of ES.

The present study summarized the occurrence of
childhood cancer and survival rates at the single
public state treatment center for oncolgic diseases
in children and adolescents. Although this was not a
population-based study, it supplies important
epidemiological data from a state where population-
based studies of childhood and adolescent cancer do
not exist.

The clinical outcomes of the children and adoles-
cents included in this sample reflect the health care
that they received in both primary and tertiary care.
The survival rate found in this analysis still lies
below that found in developed countries’ population
reports\textsuperscript{23,24} and should serve as a framework for
future improvements, helping to guide policymakers
to focus on pediatric oncology in the state of ES.

\section*{References}

1. Instituto Nacional de Câncer. Estimativa 2012: incidência

2. Magrath I, Stelianova-Foucher E, Epelman S, Ribeiro RC,
Harif M, Li CK, Kebudi R, Macfarlane SD, Howard SC.
Paediatric cancer in low-income and middle-income

3. De Camargo B, de Oliveira Santos M, Rebelo MS, Reis RS,
Ferman S, Noronha CP, Pombo-de-Oliveira MS. Cancer
incidence among children and adolescents in Brazil: First
report of 14 population-based cancer registries. Int J
Cancer. 2010; 126: 715-20.

Terenziani M. Childhood cancer survival trends in Europe: a
23: 3742-51.

5. Smith MA, Seibel NL, Altekruse SF, Ries LS, Melbert
DL, O’Leary M, Smith FO, Reaman GH. Outcomes for
children and adolescents with cancer: challenges for the
2625-34.

survival from childhood cancer in Britain during 1978-2005
by eras of entry to clinical trials. Ann Oncol. 2012; 23:
2464-9.

7. Arora B, Banavali SD. Pediatric oncology in India: past,
present and future. Indian J Med Paediatr Oncol. 2009;
30: 121-3.

8. Pritchard-Jones K, Sullivan R. Children with cancer:
driving the global agenda. Lancet Oncol. 2013; 14:
189-91.

9. Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui
CH, Robison LL, Ribeiro RC. Childhood cancer epidemi-
ology in low-income countries. Cancer. 2008; 112:
461-72.

10. Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L,
Downie P, Calaminus G, Naafs-Wilstra MC, Stelianova-
Foucher E. Sustaining innovation and improvement in the
treatment of childhood cancer: lessons from high-income

Informações de Saúde. Estatísticas vitais. Mortalidade 2011
[access Jul 07, 2013]. Available at:
http://www.datasus.gov.br

2006.

Childhood and adolescent cancer in Brazil: data from
mortality and population-based registries. Rio de Janeiro:
National Cancer Institute, 2009. [access Jun 20, 2013].
Available at: http://www2.inca.gov.br/wps/wcm/connect/inca/portal/hom
e

14. Reis RS, Santos MO, Thuler LCS. Incidência de tumores
5-15.

15. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat

16. Arora RS, Eden T, Kapoor G. Epidemiology of childhood

17. Braga PE, Latorre MRDO, Curado MP. Câncer na infância:
análise comparativa da incidência, mortalidade e sobrevida
em Goiânia (Brasil) e outros países. Cad Saúde Pública.

Incidência, mortalidade e sobrevida do câncer da infância
no município de São Paulo. São Paulo: Tomgraf Editora;
cacoes/inca/registro_de_cancer_2004pdf

19. Pinho RS, Andreoni S, Silva NS, Cappellano AM, Matsu
MR, Carvalheiro S, Vilanova LCP. Pediatric central nervous
system tumors: a single-center experience from 1989 to

20. Pedrosa MF, Pedrosa F, Lins MN, Pontes NT, Hanois Falbo
G. NonHodgkin’s lymphoma in childhood: clinical and
epidemiological characteristics and survival analysis at a
83: 547-54.

21. Magrath I. Epidemiology: clues to the pathogenesis of

22. Figueira-Silva CM, Pereira FEL. Prevalence of Epstein-
Barr virus antibodies in healthy children and adolescents in


